Fosun Pharmaceuticals announced that on September 14, 2026, the company repurchased 1.455 million H shares on the Hong Kong Stock Exchange, accounting for 0.27% of the shares issued before the repurchase. The repurchase price range for each share was HK$16.30 to HK$17.14. The total repurchase amount was HK$247.51 million, and the purchased shares were intended to be held as treasury shares. The repurchase is based on the repurchase authorization passed by the shareholders' meeting on June 16, 2026. The total number of shares that can be repurchased under this authorization is 54.907 million shares. Up to now, 4.859 million shares have been repurchased, accounting for 0.9% of the shares issued on the authorization date. The 30-day period after this repurchase is a suspension period for the issuance of new shares and the sale/transfer of treasury shares, until October 14, 2026.

Fosun Pharmaceuticals announced that on September 14, 2026, the company repurchased 1.455 million H shares on the Hong Kong Stock Exchange, accounting for 0.27% of the shares issued before the repurchase. The repurchase price range for each share was HK$16.30 to HK$17.14. The total repurchase amount was HK$247.51 million, and the purchased shares were intended to be held as treasury shares. The repurchase is based on the repurchase authorization passed by the shareholders' meeting on June 16, 2026. The total number of shares that can be repurchased under this authorization is 54.907 million shares. Up to now, 4.859 million shares have been repurchased, accounting for 0.9% of the shares issued on the authorization date. The 30-day period after this repurchase is a suspension period for the issuance of new shares and the sale/transfer of treasury shares, until October 14, 2026.